Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Inclusion Criteria

• •Age range 14-70 years old; ECOG performance status 0-2.
• •Estimated survival time \> 6 months.
• •Histological confirmed diffuse large B cell lymphoma.
• •Have taken first-line chemotherapy regimen and failed.
• •None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.
• •At least one measurable lesion.
• •None of other serious diseases, cardiopulmonary function is normal.
• •Pregnancy test of women at reproductive age must be negative.
• •Patients could be followed up.
• •None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
• •Volunteers who signed informed consent.